Why the study?
With population aging, characterizing frailty and comorbidity burden is increasingly important, motivating this analysis in patients with AF compared to those without AF.
What are the independent factors associated with atrial fibrillation in an elderly outpatient population?
What are the independent factors associated with atrial fibrillation in an elderly outpatient population?
Elderly patients with atrial fibrillation have a higher burden of frailty, comorbidities, and polypharmacy compared to those without AF.
Higher frailty and comorbidity burden in geriatric AF patients support integrated CGA; leaves open whether they drive outcomes or guide therapy.
Background: With the aging of the population, the characterization of frailty and comorbidity burden is increasingly taking on particular importance. The aims of the present study are to analyze such conditions in a population affected by Atrial Fibrillation (AF), matching it with a population without AF, and to recognize potential independent factors associated with such common cardiovascular disease. Methods: This study included subjects consecutively evaluated over 5 years at the Geriatric Outpatient Service, University Hospital of Monserrato, Cagliari, Italy. A sum of 1981 subjects met the inclusion criteria. The AF-group was made up of 330 people, and another 330 people were randomly selected to made up the non-AF-group. The sample was subjected to Comprehensive Geriatric Assessment (CGA). Results: = 0.03). The multivariate analysis (AUC: 0.808) showed that the presence of AF was independently positively associated with a history of coronary heart disease (OR: 2.12) and cerebrovascular disease (OR: 1.64), with the assumption of Beta Blockers (OR: 3.39), and with the number of drugs taken (OR: 1.12), and negatively associated with the assumption of antiplatelets (OR: 0.09). Conclusions: Elderly people with AF are frailer, have more severe comorbidities, and take more drugs, in particular beta blockers, than people without AF, who conversely have a higher survival probability. Furthermore, it is necessary to pay attention to antiplatelets, especially in AF-group, in order to avoid dangerous under- or over-prescriptions.
No takes yet. Share an insight, caveat, or question.
Salis et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: